Advanced Chemotherapy Technologies
Raleigh, US · Delaware corporation
Founders & leadership
JJ
Jen Jen YehNamed on SEC filing
AS
Anthony S. VoiersNamed on SEC filing
JD
Joseph DeSimoneNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$6.4M disclosed across 2 rounds · 2020–2024
▶$950KraisedMar 2024 · 2 investors · BiotechnologyRule 506(b)
▶$950KraisedMar 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nessan BerminghamDirector
- Jen Jen YehDirector
- Joseph DeSimoneDirector
- Michael AldridgeExecutive Officer, Director
- Offering amount
- $950K
- Amount sold
- $950K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$5.5MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jen Jen YehDirector
- Anthony S. VoiersExecutive Officer, Director, Promoter
- Joseph DeSimoneDirector
- Offering amount
- $14.1M
- Amount sold
- $5.5M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Advanced Chemotherapy Technologies raised?
- Advanced Chemotherapy Technologies has disclosed $6.4M raised across 2 rounds.
- Where is Advanced Chemotherapy Technologies headquartered?
- Advanced Chemotherapy Technologies is headquartered in Raleigh, US.